Prior to founding Medical Minds, our team created prelaunch educational programs related to Lucentis®, now a standard of care in age-related macular degeneration (AMD).
We’ve followed this market as it has developed over the years, and recently we were able to contribute to another breakthrough treatment introduced in Europe and in clinical trials in the US:
- Oraya—IRay® noninvasive, stereotactic radiosurgery for the treatment of wet AMD: Qualitative and quantitative market research and patient education to support product introduction into the UK See case study
In addition, we have recently developed an educational program focusing on the treatment of diabetic macular edema (DME).